These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Black and white teas as potential agents to combine with amphotericin B and protect red blood cells from amphotericin B-mediated toxicity. Oliveira VM; Khalil NM; Carraro E Braz J Biol; 2018 Nov; 78(4):673-678. PubMed ID: 29412247 [TBL] [Abstract][Full Text] [Related]
3. Identification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against Cryptococcus neoformans and Rossi SA; de Oliveira HC; Agreda-Mellon D; Lucio J; Mendes-Giannini MJS; García-Cambero JP; Zaragoza O Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988099 [TBL] [Abstract][Full Text] [Related]
4. Antifungal drug combinations for Cryptococcus neoformans and Prototheca spp. Srimuang S; Prariyachatigul C; Chaiprasert A; Rungsipanuratn W; Tanphaichitra D J Med Assoc Thai; 2000 Jan; 83(1):57-60. PubMed ID: 10710870 [TBL] [Abstract][Full Text] [Related]
5. In vitro activity of voriconazole and amphotericin B against Candida albicans, Candida krusei, and Cryptococcus neoformans in human cerebrospinal fluid. Al Jalali V; Sauermann R; Eberl S; Zeitlinger M Infection; 2019 Aug; 47(4):565-570. PubMed ID: 30725316 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies. Nooney L; Matthews RC; Burnie JP Diagn Microbiol Infect Dis; 2005 Jan; 51(1):19-29. PubMed ID: 15629225 [TBL] [Abstract][Full Text] [Related]
7. Enhanced diallyl trisulfide has in vitro synergy with amphotericin B against Cryptococcus neoformans. Shen J; Davis LE; Wallace JM; Cai Y; Lawson LD Planta Med; 1996 Oct; 62(5):415-8. PubMed ID: 8923805 [TBL] [Abstract][Full Text] [Related]
8. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans. Klepser ME; Wolfe EJ; Pfaller MA J Antimicrob Chemother; 1998 Mar; 41(3):397-401. PubMed ID: 9578168 [TBL] [Abstract][Full Text] [Related]
9. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726 [TBL] [Abstract][Full Text] [Related]
10. A flow cytometry method for testing the susceptibility of Cryptococcus spp. to amphotericin B. Benaducci T; Matsumoto MT; Sardi JC; Fusco-Almeida AM; Mendes-Giannini MJ Rev Iberoam Micol; 2015; 32(3):159-63. PubMed ID: 25639695 [TBL] [Abstract][Full Text] [Related]
11. Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole. Khyriem AB; Sujatha S; Parija SC Indian J Pathol Microbiol; 2006 Apr; 49(2):307-8. PubMed ID: 16933750 [TBL] [Abstract][Full Text] [Related]
12. Antiphagocytic protein 1 increases the susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole. Ghaffar M; Orr C; Webb G PLoS One; 2019; 14(12):e0225701. PubMed ID: 31800598 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. Schwarz P; Dromer F; Lortholary O; Dannaoui E Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675 [TBL] [Abstract][Full Text] [Related]
14. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia. Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082 [TBL] [Abstract][Full Text] [Related]
15. Synergistic effect of pedalitin and amphotericin B against Cryptococcus neoformans by in vitro and in vivo evaluation. Sangalli-Leite F; Scorzoni L; Alves de Paula E Silva AC; da Silva JF; de Oliveira HC; de Lacorte Singulani J; Gullo FP; Moraes da Silva R; Regasini LO; Siqueira da Silva DH; da Silva Bolzani V; Fusco-Almeida AM; Soares Mendes-Giannini MJ Int J Antimicrob Agents; 2016 Nov; 48(5):504-511. PubMed ID: 27742203 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology. Keele DJ; DeLallo VC; Lewis RE; Ernst EJ; Klepser ME Diagn Microbiol Infect Dis; 2001 Nov; 41(3):121-6. PubMed ID: 11750164 [TBL] [Abstract][Full Text] [Related]
17. The postantibiotic effect of antifungal agents against common pathogenic yeasts. Turnidge JD; Gudmundsson S; Vogelman B; Craig WA J Antimicrob Chemother; 1994 Jul; 34(1):83-92. PubMed ID: 7961219 [TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of a dried commercially prepared microdilution panel for antifungal susceptibility testing of five antifungal agents against Candida spp. and Cryptococcus neoformans. Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ Diagn Microbiol Infect Dis; 2004 Oct; 50(2):113-7. PubMed ID: 15474320 [TBL] [Abstract][Full Text] [Related]
19. Enhanced activity of antifungal drugs using natural phenolics against yeast strains of Candida and Cryptococcus. Faria NC; Kim JH; Gonçalves LA; Martins Mde L; Chan KL; Campbell BC Lett Appl Microbiol; 2011 May; 52(5):506-13. PubMed ID: 21332761 [TBL] [Abstract][Full Text] [Related]
20. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Johnson EM; Ojwang JO; Szekely A; Wallace TL; Warnock DW Antimicrob Agents Chemother; 1998 Jun; 42(6):1412-6. PubMed ID: 9624486 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]